BNT162b4 / Pfizer, BioNTech - LARVOL DELTA

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People (clinicaltrials.gov) - P1 | N=383 | Completed | Sponsor: BioNTech SE | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Machine learning-enhanced immunopeptidomics applied to T-cell epitope discovery for COVID-19 vaccines. (PubMed, Nat Commun) - "Our EpiTrack pipeline tracks global mutations of MHCvalidator-identified CD8 + T-cell epitopes from the BNT162b4 vaccine. While most vaccine epitopes remain globally conserved, an immunodominant A*01-associated epitope mutates in Delta and Omicron variants. This work highlights SARS-CoV-2 antigenic features and emphasizes the importance of continuous adaptation in T-cell vaccine development."

Journal • Machine learning • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People (clinicaltrials.gov) - P1 | N=383 | Active, not recruiting | Sponsor: BioNTech SE | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People (clinicaltrials.gov) - P1 | N=380 | Recruiting | Sponsor: BioNTech SE | Active, not recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People (clinicaltrials.gov) - P1 | N=360 | Active, not recruiting | Sponsor: BioNTech SE | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People (clinicaltrials.gov) - P1 | N=360 | Recruiting | Sponsor: BioNTech SE | N=240 ➔ 360 | Trial completion date: Nov 2023 ➔ Oct 2024 | Trial primary completion date: Nov 2023 ➔ Oct 2024

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"Das passiert durchaus, nur ist das Thema jetzt weniger glorreich als 2020. 😉 BNT162b4 klingt schonmal super: https://t.co/oCpNfwjT8T" (@Bernsteiniel)

"🤔😲 Consequences? @AngelaReiersen @boulware_dr "BNT162b4 encodes conserved, immunogenic segments of the SARS-CoV-2 N, M, and ORF1ab antigens"" (@Woodynist)

Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection. (PubMed, Cell) - P1 | "These data suggest that a combination of BNT162b2 and BNT162b4 could reduce COVID-19 disease severity and duration caused by circulating or future variants. BNT162b4 is currently being clinically evaluated in combination with the BA.4/BA.5 Omicron-updated bivalent BNT162b2 (NCT05541861)."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Safety and Effects of an Investigational COVID-19 Vaccine as a Booster in Healthy People (clinicaltrials.gov) - P1 | N=240 | Recruiting | Sponsor: BioNTech SE | N=180 ➔ 240

Enrollment change • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Effects of an Investigational COVID-19 Vaccine as a Booster in Healthy People (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: BioNTech SE | Trial primary completion date: May 2023 ➔ Nov 2023

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Effects of an Investigational COVID-19 Vaccine as a Booster in Healthy People (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Effects of an Investigational COVID-19 Vaccine as a Booster in Healthy People (clinicaltrials.gov) - P1 | N=180 | Not yet recruiting | Sponsor: BioNTech SE

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases